Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Algopedol is a 24% sucrose (saccharose) oral solution developed and distributed by Laboratoires Crinex. It is specifically designed for use in newborns and infants up to four months of age to provide comfort and manage pain during minor medical procedures, such as blood sampling, vaccinations, and dressing removals. Classified as a Class I medical device in France, the solution is preservative-free and packaged in 2 ml single-dose units. Its mechanism of action relies on the analgesic effect of oral sucrose, which is believed to stimulate the release of endogenous opioids; this effect is significantly enhanced when the administration is combined with non-nutritive sucking.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Algopedol.